Optimization of pharmaceutical therapy of erosive and ulcerative lesions of the gastroduodenal zone in elective surgical patients

The objective was to improve the results of treatment of surgical patients in the perioperative period with concomitant erosive and ulcerative lesions of the gastroduodenal zone.

Methods abd materials. 41 patients receiving inpatient care were observed from March to December 2024. The results of the study were registered for the following stages: 1 – the control before prescribing the drug, 2 – after 3–5 days of therapy with Omeprazole/Lanson-AF. All patients included in the study were assessed at stages 1 and 2 according to the dynamics of the main general clinical and biochemical laboratory parameters and the results of fibrogastroduodenoscopy (FGDS). Statistical data processing was performed using the IBM SPSS Statistics 20 program.

Results. According to FGDS data, defects of the gastroduodenal mucosa of varying severity were detected in patients at the 1st stage of the study. After the 1st stage, patients were divided into 2 groups: control and comparison. Antisecretory therapy with Omeprazole was performed in the control group, and Lanson-AF was performed for 3–4 days in the comparison group. In the control FGDS, there was a decrease in hyperemia, edema, and the absence of a visible defect in the gastric and/or duodenal mucosa. With Omeprazole, ulcerative defect repair was achieved by 3–4 days in 40 % of patients, with Lanson-AF in 92 % of cases.

Conclusion. The appointment of the drug Lanson-AF is more effective than Omeprazole for the purpose of preoperative preparation of patients with defects of the gastric and/ or duodenal mucosa for elective surgery. No adverse events have been reported with the use of Lanson-AF.

1. Lu R., Yang B. Incidence and influencing factors of acute gastrointestinal injury after cardiac surgery. BMC Cardiovasc Disord. 2023;(23):437. https://doi.org/10.1186/s12872-023-03475-6

2. Kutukov V. V., Zaitsev I. V., Dzhanibekova Д. E. Prevention of acute erosions and ulcers of esophagus and stomach after oncologic operations on kidneys. Eurasian Union of Scientists. 2016;(4–3(25)):115–117. (In Russ.). EDN XCMGID.

3. Kostyuchenko M. V. Acute erosive-ulcerous lesions of the stomach at surgical endotoxicosis and methods of their prophylaxis. Medical Alphabet. 2016;1(5: Practical gastroenterology):41–45. (In Russ.).

4. Gurusamy K. S., Pallari E. Medical versus surgical treatment for refractory or recurrent peptic ulcer. Cochrane Database of Systematic Reviews. 2016;(3):CD011523. https://doi.org/10.1002/14651858.CD011523.pub2.

5. Clarke K., Adler N., Agrawal D et al. Indications for the Use of Proton Pump Inhibitors for Stress Ulcer Prophylaxis and Peptic Ulcer Bleeding in Hospitalized Patients. Am J Med. 2022;(Is.135, № 3):313–317. https://doi.org/10.1016/j.amjmed.2021.09.010.

6. Kaigorodtseva N. V., Plotkin L. L., Sagidullin А. V. et al. Efficacy of a new proton pump inhibitor in patients in critical condition. Bulletin of Chelyabinsk Regional Clinical Hospital. 2024;59(1):2–3. (In Russ.).

7. Kostina A. A., Kulakova D. A., Aksenova T. A. Proton pump inhibitor drugs: the problem of choice. International Student Scientific Bulletin. 2021;(2):172. (In Russ.).

8. Saade M. C., Kerbage A., Jabak S. et al. Validation of the new ABC score for predicting 30-day mortality in gastrointestinal bleeding. BMC Gastroenterol. 2022;(22):301. https://doi.org/10.1186/s12876-022-02374-y